Press Releases

Print Page   Print Page       E-mail Page   Email Page       RSS Feeds   RSS       E-mail Alerts  Email Alerts       Financial Tear Sheet  Tear Sheet

Press Releases

Date Title
01/28/20 Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder
01/08/20 Alkermes' Corporate Presentation to be Webcast at the 38th Annual J.P. Morgan Healthcare Conference
12/12/19 Alkermes Media Statement Regarding FDA Warning Letter
11/26/19 Alkermes to Present at the Evercore ISI 2nd Annual HealthCONx Conference
11/25/19 Alkermes Completes Acquisition of Rodin Therapeutics
11/19/19 Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder
11/18/19 Alkermes to Acquire Rodin Therapeutics
11/12/19 Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences
11/12/19 Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY™
11/08/19 Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
11/04/19 Alkermes to Present Data From ALKS 4230 Clinical Development Program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
10/30/19 Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis
10/23/19 Alkermes Plc Reports Third Quarter 2019 Financial Results and Implementation of Restructuring
10/21/19 Alkermes Announces Clinical Collaboration With Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230
10/16/19 Alkermes to Host Conference Call to Discuss Third Quarter 2019 Financial Results
Displaying 46 - 60 of 795